CTLA4 and melanoma: In a phase III trial comparing the efficacy of a 10 mg/kg dose of ipilimumab with that of a 3 mg/kg dose administered on the same schedule in patients with previously treated advanced-stage melanoma, patients in the high-dose anti-CTLA-4 antibody (ipilimumab) group had an increased prevalence of grade ≥3 adverse events.46